# SANA — replay s9 — bf16

## Metadata

ticker: SANA
arm: bf16
sample: 9
served_name: financial-lora
source_findings: eval/runs/raw/v924f-findings/SANA_local-model.md
context_sha256: 03e6bdab74ad2102adf024d5f44d8c25f69c6ba19acc4870607d569ceca09ae2
agent_core_sha256: f45e278f9722d5c331843a77692b154904f72edd059e6a3da48976a7945db44e
sampling: {"temperature": 0.1, "max_tokens": 512, "top_p": 0.8, "top_k": 20, "repetition_penalty": 1.1, "min_p": 0.0}
endpoint: http://localhost:30880
generated_utc: 2026-09-30T04:48:58Z
financial_health_prompt_sha256: 0a7f61736a0b9867773ff7db9508225e9a13499f7330cee4b00e8cebbb7ed76d
financial_health_seed: 1090270
financial_health_response_model: financial-lora
financial_health_finish_reason: stop
financial_health_completion_tokens: 95
risk_factors_prompt_sha256: f9aa231716879b9188636cec364f613a0e910dd13e3e5de132fec68b9fe09366
risk_factors_seed: 1090271
risk_factors_response_model: financial-lora
risk_factors_finish_reason: length
risk_factors_completion_tokens: 512

## Stock data

{
  "ticker": "SANA",
  "company_name": "Sana Biotechnology, Inc.",
  "current_price": 3.08,
  "currency": "USD",
  "market_cap": 922030720.0,
  "forward_pe": -5.54845,
  "week_52_high": 6.55,
  "week_52_low": 2.61,
  "net_income": -211822000.0,
  "profit_margin": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

<!-- replay-section: Financial Health -->
### Financial Health

Sana Biotechnology, Inc., trades under the ticker symbol "SANA" on the Nasdaq Capital Market. It carries a current market capitalization of $92.2 billion and a forward P/E ratio of -5.5x. Over the past year, the company has reported net income of -$21.2 billion and a net profit margin of 0%. The company's sector is Healthcare and its industry is Biotechnology.

<!-- replay-section: Risk Factors -->
### Primary Risk Factors Disclosed

The company faces various material risks, which can be categorized into several key areas:

#### 1. **Technology and Development Risks**
   - The company relies on innovative cell engineering platforms that are based on novel, unproven technologies. These technologies may not prove successful in identifying, developing, and commercializing product candidates.
   - Additionally, the company is unable to successfully identify, develop, and commercialize product candidates. This failure could lead to substantial doubt regarding the company’s ability to continue as a going concern.
   - Furthermore, the company needs additional funding to finance its operations, with potential inability to raise capital on acceptable terms.
   - Additionally, the company may experience significant delays in commencing clinical trials due to preclinical testing being delayed or unsuccessful.
   - Moreover, the company may experience significant delays in commencing clinical trials due to clinical trial data being insufficiently robust or reliable.
   - Finally, the company may experience significant delays in commencing clinical trials due to clinical trial protocols being deemed inappropriate or non-compliant with applicable regulations and guidelines.

#### 2. **Financial and Operational Risks**
   - The company depends on retaining key personnel and recruiting qualified staff. If the company fails to retain these individuals or recruit sufficient numbers of qualified staff, it will be difficult for the company to achieve its operational goals and objectives.
   - The company also experiences difficulty in realizing benefits from acquired or in-licensed technologies. If the company is unable to realize such benefits, it will have a negative impact on the company’s financial performance and results of operations.
   - The company also experiences difficulty in entering into or realizing benefits from strategic relationships. If the company is unable to enter into such relationships or realize the associated benefits, it will have a negative impact on the company’s financial performance and results of operations.
   - The company also experiences difficulty in managing growth and expansion of operations. If the company is unable to effectively manage such growth and expansion, it will have a negative impact on the company’s financial performance and results of operations.

#### 3. **Personnel and Strategic Risks**
   - The company relies on retaining key personnel and recruiting qualified staff. If the company fails to retain these individuals or recruit sufficient numbers of qualified staff, it will be difficult for the company to achieve its operational goals and objectives.
   - The company also experiences difficulty in realizing benefits from acquired or in-licensed technologies. If the company is unable to realize such benefits, it will have a negative impact on the company’s financial
